Showing 4611-4620 of 5771 results for "".
- TearLab Appoints Adam Szaronos as Chief Commercial Officerhttps://modernod.com/news/tearlab-appoints-adam-szaronos-as-chief-commercial-officer/2478094/TearLab announced the appointment of Adam Szaronos to the position of Chief Commercial Officer (CCO). Mr. Szaronos brings a wealth of experience gained over the past 15 years and will help guide the evolution of TearLab as it
- New Licensing Agreement Accelerates the Development of IACTA Pharmaceuticals’ Novel Dry Eye Disease and Allergic Conjunctivitis Treatments in China and Southeast Asiahttps://modernod.com/news/new-licensing-agreement-accelerates-the-development-of-iacta-pharmaceuticals-novel-dry-eye-disease-and-allergic-conjunctivitis-treatments-in-china-and-southeast-asia/2478088/IACTA Pharmaceuticals and Zhaoke Ophthalmology Pharmaceutical (ZKO), a Hong Kong-based pharmaceutical company, announced they have entered into a definitive license agreement on the licensing of two of the company’s products, IC 265 for dry eye and IC 270 fo
- Dosing Begins in Moderna’s Late-Stage Study of COVID-19 Vaccine Candidatehttps://modernod.com/news/dosing-begins-in-modernas-late-stage-study-of-covid-19-vaccine-candidate/2478085/Moderna announced that patient dosing started in the phase 3 COVE study of its mRNA-based vaccine candidate against the novel coronavirus, sending company shares up as much as 11.3% on Monday. The trial of mRNA-1273 is being conducted in collaboration with the US National Institute of Allergy and
- New Novartis Analysis Examines Sustainable Fluid Control of Beovu Compared With Aflibercepthttps://modernod.com/news/new-novartis-analysis-shows-wet-amd-patients-achieved-sustained-fluid-control-faster-with-beovu-versus-aflibercept/2478080/Novartis announced results of a new post-hoc analysis of Beovu (brolucizumab) phase 3 HAWK and HARRIER pivotal trials demonstrating faster sustainable fluid control when compared with aflibercept in patients with wet
- Ocugen Granted FDA Orphan Drug Designation for Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Diseasehttps://modernod.com/news/ocugen-granted-fda-orphan-drug-designation-for-gene-therapy-for-the-treatment-of-rho-mutation-associated-retinal-degenerative-disease/2478081/Ocugen announced the FDA granted the third orphan drug designation (ODD) for OCU400 in the treatment of RHO mutation-associated retinal degeneration. The RHO mutation is part of the retinitis pigmentosa (RP) group of rare, genetic disorders that involve a breakdown and loss of
- US to PayNearly $2 Billion for 100 Million Doses of Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/us-to-paynearly-2-billion-for-100-million-doses-of-pfizer-biontechs-covid-19-vaccine/2478067/Pfizer and BioNTech announced that the US government agreed to pay $1.95 billion for an initial order of 100 million doses of BNT162, an mRNA-based COVID-19 vaccine candidate being jointly developed by the companies. Under the deal, the government can also acquire up to 500 million more doses.
- Aurinia Prices $200 Million Public Offering of Common Shareshttps://modernod.com/news/aurinia-prices-200-million-public-offering-of-common-shares/2478066/Aurinia Pharmaceuticals, a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announced the pricing of its underwritten public offering of 13,333,334 common shares. The company is currently developing the investig
- Phase 3 Data Show Port Delivery System With Ranibizumab Enabled Over 98% of Patients to Go 6 Months Between Treatments for Wet AMDhttps://modernod.com/news/phase-3-data-show-port-delivery-system-with-ranibizumab-enabled-over-98-of-patients-to-go-6-months-between-treatments-for-wet-amd/2478061/Genentech announced detailed results from the phase 3 Archway study evaluating its investigational Port Delivery System with ranibizumab (PDS) for the treatment of wet age-related macular degeneration (AMD). In Archway, 98.4% of PDS patients were able to go 6 months without needing additio
- Rayner to Lower Carbon Footprint by More Than 800 Tons Over 5 Yearshttps://modernod.com/news/rayner-to-lower-carbon-footprint-by-more-than-800-tonnes-over-5-years/2478056/Rayner announced that changes to their manufacturing and packaging procedures will reduce CO2 greenhouse gas emissions by more than 800 tons over the next 5 years. The reduced CO2 greenhouse gas emissions are the result of three dedicated waste-reducing projects:
- Alcon Survey Shows More Screen Time Causing Consumer Concern About Eye Health, Increasing Symptoms of Dry Eyehttps://modernod.com/news/alcon-survey-shows-more-screen-time-causing-consumer-concern-about-eye-health-increasing-symptoms-of-dry-eye/2478054/Alcon announced the results of a new survey, conducted by research firm Ipsos among 1,005 US adults, that uncover the impact the COVID-19 pandemic is having on consumers’ screen time and how that impacts their perceptions on eye health. Key findings include: Nearly 80% of Americans r